Time lim­its on ac­cel­er­at­ed ap­provals? FDA's on­col­o­gy chief Rick Paz­dur eyes po­ten­tial re­forms via in­ter­na­tion­al ap­proach­es

The spot­light on the ac­cel­er­at­ed ap­proval path­way con­tin­ues to shine bright, with the FDA’s top on­col­o­gy of­fi­cial writ­ing in an opin­ion that the path­way may …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER